

ABBREVIATED CURRICULUM VITAE
Calendar Year 2021

Name: **Shaomeng Wang, PhD**

Date of Appointment & Current Title:

2006-present: Professor with tenure, Department of Internal Medicine, School of Medicine, University of Michigan, Ann Arbor, Michigan.
2006-present: Professor, Departments of Pharmacology, School of Medicine, University of Michigan, Ann Arbor, Michigan.
2006-present: Professor, Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan.
June 2007-present: Warner-Lambert/Parke Davis Professor in Medicine, University of Michigan Medical School, Ann Arbor, Michigan.

Current U-M Leadership & Administrative Roles

Start Date	Role
April 2004-2020:	Co-Director, Molecular Therapeutics Program, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor
June 2007-present:	Director, Cancer Drug Discovery Program, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan.
2008-present	Tenure and Promotion Committee, the Center for Computational Medicine and Biology, University of Michigan.
October 2012-present	Director, Therapeutics Discovery, Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan.
April 2016-present	Director, Michigan Center for Therapeutic Innovation, University of Michigan, Ann Arbor, Michigan.

Honors & Awards Received in 2020

Date	Award Name (Indicate if International, National or Local/Institutional)
2021	Inducted into American Chemical Society Division of Medicinal Chemistry Hall of Fame

Current Memberships in Professional Societies

Start Date	Society Name
1993 – present	American Chemical Society
1996 – present	American Association for the Advancement of Science
1996 – present	American Association for Cancer Research

Current Editorial Boards

Start Date **Position on Board, Name of Publication (Do Not List Peer Reviews Here)**

Editorial Board member, Journal of Medicinal Chemistry: 2008-present.

board member, ACS Medicinal Chemistry Letters, 2010-present.

Editorial board member, Molecular Cancer Therapeutics, AACR, 2010-present.

Peer Reviews Conducted for Journals in 2021

Cell

Cancer Cell

Nature Chemistry

Nature Chemical Biology

Nature Communications

PNAS

Journal of the American Chemical Society

Journal of Medicinal Chemistry

Angewandte Chemie International Edition

Bio-organic and Medicinal Chemistry Letters

Bio-organic and Medicinal Chemistry

Journal of the National Cancer Institute

Oncogene

Cancer Research

Clinical Cancer Research

Study Section Reviews in 2021 - List of Study Sections (indicate if Ad Hoc)

NCI Center Grant Site visit team (University of Kansas Cancer Center)

NCI Chemical Biology Center

Current Non-UM Committee and Administrative Services

Start Date **Position, Name of Committee (Indicate if International, National or Local)**

Community/Volunteer Service

Start Date **Position and Agency**

Current Trainees - List Name and Degree

Wenbin Tu, Ph.D. student. Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, (2018-present).

Junius Thomas, Ph.D. student, Chemical Biology program, University of Michigan, (2018-present).

Atsunori Kaneshige, Ph.D. Student Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, (2017- present).

Lijie Zhao, Ph.D., Zhengzhou University, China, Postdoctoral Fellow, (2018-present)

Jianfeng Lu, M.D. Ph.D. Peking University Medical School, Postdoctoral Fellow, Research Investigator, Research Assistant Scientist, 1/2005-present.

Longchuan Bai, Ph.D. Peking Normal University, Research Investigator, Research Assistant Scientist, Research Associate Scientist 1/2007-present.

Haibin Zhou, Ph.D. Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Postdoctoral Fellow, Research Investigator, Assistant research scientist, 9/2007-present.

Angelo Aguilar, Ph.D., Regis University, B. Sc. in Chemistry, Kansas State University, Ph.D. Postdoctoral Fellow, 1/2009-present.

Rohan Rej, Ph.D. Indian Institute of Technology Kharagpur, 10/2016-present, postdoctoral fellow, Research Investigator

Mi Wang, Ph.D. Research Investigator, 2017-present

Bukeyan Miao, Ph.D. SIOC, Chinese Academy of Sciences, 8/2017-present, postdoctoral fellow

Changwei Wang, Ph.D. Stony Brook University, 10/2018-present, postdoctoral fellow

Andrea D. Thompson, M.D, PhD, University of Michigan, 4/2021, Clinical Lecturer and Research Fellow

Dimin Wu, Ph.D., Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 01/2020-present, postdoctoral fellow

Zhixiang Chen, Ph.D., Shanghai Institute of Organic Chemistry, CAS, 01/2020-present, postdoctoral fellow

Lin Yang, Ph.D., Department of Chemistry and Biochemistry University of Texas at Austin, Austin, 2/2021-present, postdoctoral fellow

Ranjan Kumar Acharyya, Ph.D., Indian Institute of Technology Kharagpur, India, 5/2021-present, postdoctoral fellow

Lijie Zhao, Ph.D., University of Michigan and Zhengzhou University, China, 6/2021-present, postdoctoral fellow

Yuk-Ming Siu, Ph.D., University of Texas at Austin, 8/2021-present, postdoctoral fellow

Peihua Guo, Shanghai HENGRUI Pharmaceutical Co. Ltd., 8/2021-present, postdoctoral fellow

Linying Leng, Department of Biochemistry, UT Southwestern Medical Center, 9/2021-present, postdoctoral fellow

Intramural Presentations 2021

Date	Title of Presentation, Conference/Seminar Name
June 23, 2021:	“Induced Protein Degradation: A New Paradigm in Drug Discovery”, University of Michigan Ovarian Cancer Group.
October 25, 2021:	“Induced Protein Degradation: A New Paradigm in Drug Discovery” 2021 University of Michigan Drug Discovery Symposium.

Extramural Invited Presentations 2021

Date	Title of Presentation, Conference/Seminar Name
February 16, 2021	"Discovery of first-in-class degraders of STAT3 for the treatment of human cancers", Kisaco Research, North American Protein Degradation Congress Virtual Summit
March 27, 2021:	“Induced Protein Degradation: A New Paradigm for Drug Discovery and Development”, Keynote in Sino-American Biotechnology and Pharmaceutical Professional Association

(SABPA).

- April 16, 2021: “Induced Protein Degradation: A New Paradigm for Drug Discovery and Development”, Keynote in Frontiers in Drug Discovery Symposium, Zhengzhou University, China.
- May 20, 2021: “Targeting Epigenetics for Therapeutics Discovery: From Inhibition to Degradation”, University of Minnesota Epigenetics Consortium Seminar.
- May 22, 2021: “Induced Protein Degradation: A New Paradigm in Drug Discovery” Keynote in 2021 Sino-American Pharmaceutical Professionals Association Scientific Symposium: Science Today, Life-Saving Medicines Tomorrow.
- May 27, 2021: “Induced Protein Degradation: A New Paradigm in Drug Discovery”, Keynote in the SKL of Chemical Biology and Drug Discovery of the Hong Kong Polytechnic University (PolyU).
- June 25, 2021: “My 20-Year Journey of Academic Drug Discovery Research”, American Chemical Society Division of Medicinal Chemistry Award Lecture.
- September 8, 2021: “Induced Protein Degradation in Cancer Cells as a New Therapeutic Strategy”, British Pharmacology 2021.
- October 4, 2021: “Targeting Protein-Protein Interactions through Induced Protein Degradation”, 2021 AACR-NCI-EORTC meeting.
- October 27, 2021: “Design of Exceptionally Potent and Orally Active PROTAC AR Degraders”, 4th Targeted Protein Degradation Summit.

Patents Issued in 2021

Date	Patent Number and Name
January 26, 2021	Shaomeng Wang, et al. Piperidines as menin inhibitors, US Patent Number, 10,899,738
April 13, 2021	Shaomeng Wang, et al. Fused 1,4-diazepines as BET protein degraders, US Patent Number, 10,975,093
June 29, 2021	Shaomeng Wang, et al. Piperidines as covalent menin inhibitors, US Patent Number, 11,045,448
June 29, 2021	Shaomeng Wang, et al. Fused 1,4-diazepines as BET bromodomain inhibitors, US Patent Number, 11,046,709
September 7, 2021	Shaomeng Wang et al. Aminopyrimidines as ALK inhibitors, US Patent Number, 11,110,090.
November 9, 2021	Shaomeng Wang, et al. Pyrrolo[2,3-C]pyridines and related analogs as LSD-1 inhibitors, US Patent Number, 11,168,082.
December 7, 2021	Shaomeng Wang, et al. MDM2 protein degraders, US Patent Number, 11,192,898.

BIBLIOGRAPHY

Peer-Reviewed Publications Published in 2021 in MCV Format

Hu N, Wang F, Sun T, Xu Z, Zhang J, Bernard D, Xu S, **Wang S**, Kaminski M, Devata S, Phillips T, Malek SN. Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation. *Clin Cancer Res*. 2021 Apr 15;27(8):2301-2313. doi: 10.1158/1078-0432.CCR-20-3741. Epub 2021 Jan 8. PMID: 33419778 PMCID: PMC8046715

Zhou J, Kryczek I, Li S, Li X, Aguilar A, Wei S, Grove S, Vatan L, Yu J, Yan Y, Liao P, Lin H, Li J, Li G, Du W, Wang W, Lang X, Wang W, **Wang S**, Zou W. The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. *Nat Immunol*. 2021 Apr;22(4):460-470. doi: 10.1038/s41590-021-00888-3. Epub 2021 Mar 25. PMID: 33767425 PMCID: PMC8026726

Xu L, Chen Y, Huang Y, Sandanaraj E, Yu JS, Lin RY, Dakle P, Ke XY, Chong YK, Koh L, Mayakonda A, Nacro K, Hill J, Huang ML, Gery S, Lim SW, Huang Z, Xu Y, Chen J, Bai L, **Wang S**, Wakimoto H, Yeo TT, Ang BT, Müschen M, Tang C, Tan TZ, Koeffler HP. Topography of transcriptionally active chromatin in glioblastoma. *Sci Adv*. 2021 Apr 30;7(18):eabd4676. doi: 10.1126/sciadv.abd4676. Print 2021 Apr. PMID: 33931443 PMCID: PMC8087410

Zhou H, Lu J, Chinnaswamy K, Stuckey JA, Liu L, McEachern D, Yang CY, Bernard D, Shen H, Rui L, Sun Y, **Wang S**. Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity. *Nat Commun*. 2021 May 11;12(1):2621. doi: 10.1038/s41467-021-22924-4. PMID: 33976147 PMCID: PMC8113459

Zhou H, Bai L, Xu R, McEachern D, Chinnaswamy K, Li R, Wen B, Wang M, Yang CY, Meagher JL, Sun D, Stuckey JA, **Wang S**. SD-91 as A Potent and Selective STAT3 Degradable Capable of Achieving Complete and Long-Lasting Tumor Regression. *ACS Med Chem Lett*. 2021 May 10;12(6):996-1004. doi: 10.1021/acsmchemlett.1c00155. eCollection 2021 Jun 10. PMID: 34141084 PMCID: PMC8201759

Zhang M, Aguilar A, Xu S, Huang L, Chinnaswamy K, Sleger T, Wang B, Gross S, Nicolay BN, Ronseaux S, Harvey K, Wang Y, McEachern D, Kirchhoff PD, Liu Z, Stuckey J, Tron AE, Liu T, **Wang S**. Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression. *J Med Chem*. 2021 Jul 22;64(14):10333-10349. doi: 10.1021/acs.jmedchem.1c00789. Epub 2021 Jul 1. PMID: 34196551

Han X, Zhao L, Xiang W, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Wang L, Matvekas A, Wen B, Sun D, **Wang S**. Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degradable of Androgen Receptor for the Treatment of Prostate Cancer. *J Med Chem*. 2021 Sep 9;64(17):12831-12854. doi: 10.1021/acs.jmedchem.1c00882. Epub 2021 Aug 25. PMID: 34431670

Xiang W, Zhao L, Han X, Qin C, Miao B, McEachern D, Wang Y, Metwally H, Kirchhoff PD, Wang L, Matvekas A, He M, Wen B, Sun D, **Wang S**. Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degradable of Androgen Receptor for the Treatment of Advanced Prostate Cancer. *J Med Chem*. 2021 Sep 23;64(18):13487-13509. doi: 10.1021/acs.jmedchem.1c00900. Epub 2021 Sep 2. PMID: 34473519

Yuan S, Wang B, Dai QQ, Zhang XN, Zhang JY, Zuo JH, Liu H, Chen ZS, Li GB, **Wang S**, Liu HM, Yu B. Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. *J Med Chem.* 2021 Oct 14;64(19):14895-14911. doi: 10.1021/acs.jmedchem.1c01452. Epub 2021 Sep 21. PMID: 34546748

Tong J, Tan X, Risnik D, Gao M, Song X, Ermine K, Shen L, **Wang S**, Yu J, Zhang L. BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade. *Oncogene.* 2021 Dec;40(48):6566-6578. doi: 10.1038/s41388-021-02041-8. Epub 2021 Oct 6. PMID: 34615996 PMCID: PMC8642302 (available on 2022-04-06)

Tang J, **Wang S**, Yang L, Wu Z, Jiang H, Zeng B, Gong Y. On the molecular mechanisms implicated in the bipolar cancellation of membrane electroporation. *Biochim Biophys Acta Biomembr.* 2022 Feb 1;1864(1):183811. doi: 10.1016/j.bbmem.2021.183811. Epub 2021 Oct 29. PMID: 34744023

Peer-Reviewed Totals (Indicate "0" if None)	Total Published in 2021	1 st Author	Last/Senior Author	In Press in 2021
	11	0	5	0


Non-Peer-Reviewed Publications Published in 2020 in MCV Format

Non-Peer-Reviewed Totals (Indicate "0" if None)	Total Published in 2021	1 st Author	Last/Senior Author	In Press in 2021
	0	0	0	0

Books & Book Chapters Published in 2021 in MCV Format (Do Not Number)

Books

Book Chapters

Form Completed by		
Faculty Certification I have reviewed this data and it is correct	Faculty Signature/Date 	06/01/2022